Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
Inflammatory Bowel Diseases
|
September 26, 2024
Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients
Mathieu Uzzan, Georgi Georgiev, Laurent Peyrin-Biroulet, et al.
BMC Gastroenterology
|
July 20, 2010
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia
Yasmin Hernandez, John Sotolongo, Keith Breglio, et al.
Digestive Diseases and Sciences
|
October 24, 2019
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Andres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Digestive Diseases and Sciences
|
March 6, 2019
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Andres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Pharmaceutics
|
February 26, 2025
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Andres J Yarur, Thierry Dervieux, Ryan Ungaro, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2019
Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
Tomer Adar, David Faleck, Saranya Sasidharan, et al.
Crohn'S & Colitis 360
|
April 22, 2025
Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials
Bincy Abraham, Jianmin Wu, Séverine Vermeire, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
April 11, 2009
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis
Ryan Ungaro, Masayuki Fukata, David Hsu, et al.
Digestive Diseases and Sciences
|
May 2, 2021
Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis
Yansheng Hao, Clara Yzet, Russell B McBride, et al.
International Journal of Colorectal Disease
|
September 13, 2019
Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study
Maia Kayal, Aparna Saha, Priti Poojary, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
Inflammatory Bowel Diseases
|
September 26, 2024
Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients
Mathieu Uzzan, Georgi Georgiev, Laurent Peyrin-Biroulet, et al.
BMC Gastroenterology
|
July 20, 2010
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia
Yasmin Hernandez, John Sotolongo, Keith Breglio, et al.
Digestive Diseases and Sciences
|
October 24, 2019
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Andres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Digestive Diseases and Sciences
|
March 6, 2019
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Andres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Pharmaceutics
|
February 26, 2025
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Andres J Yarur, Thierry Dervieux, Ryan Ungaro, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2019
Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
Tomer Adar, David Faleck, Saranya Sasidharan, et al.
Crohn'S & Colitis 360
|
April 22, 2025
Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials
Bincy Abraham, Jianmin Wu, Séverine Vermeire, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
April 11, 2009
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis
Ryan Ungaro, Masayuki Fukata, David Hsu, et al.
Digestive Diseases and Sciences
|
May 2, 2021
Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis
Yansheng Hao, Clara Yzet, Russell B McBride, et al.
International Journal of Colorectal Disease
|
September 13, 2019
Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study
Maia Kayal, Aparna Saha, Priti Poojary, et al.
Page
of 7